Table 2

Summary of variables related to drug use and disease assessment in intervals

Continuous variablesTotal intervalsOn TNFi
n=1281
Off TNFi
n=1083
Duration of intervals, mean (SD), day439.1 (646.7)633.0 (721.0)209.8 (448.6)
ESR at start, mean (SD), mm/hour20.84 (23.75)23.67 (26.37)17.46 (19.66)
CRP at start, mean (SD), mg/dL1.47 (1.67)1.67 (1.96)1.23 (1.21)
BASDAI at start, mean (SD)3.52 (2.44)4.00 (2.69)2.95 (1.96)
mSASSS change per year (SD)0.85 (1.59)0.82 (1.53)0.89 (1.66)
cDMARDs* (%)165 (7.0)103 (8.0)62 (5.7)
NSAIDs* (%)516 (21.8)379 (29.6)137 (12.7)
Glucocorticoids* (%)48 (2.0)26 (2.0)22 (2.0)
  • *Number of intervals prescribed with drugs for >50% of the interval period.

  • AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; cDMARDs, conventional disease-modifying anti-rheumatic drugs; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NSAIDs, non-steroidal anti-inflammatory drugs.